Patents by Inventor Anders Hogset
Anders Hogset has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 10610582Abstract: A method of vaccination or immunisation involving the use of a photosensitizing agent, an antigenic molecule, e.g. a vaccine component, and an agent which enhances the effect of photochemical internalization (PCI)-mediated vaccination is disclosed wherein the agent is a ligand for a Toll-like receptor (TLR), and irradiation is with light of a wavelength effective to activate the photosensitizing agent. Antigenic, e.g. vaccine compositions, useful in such a method are also disclosed along with a method of generating antigen presenting cells which may be used to generate an immune response based on introducing antigenic molecules, e.g. vaccine components, into cells to achieve antigen presentation. The invention also provides methods of achieving vaccination in a subject using such cells.Type: GrantFiled: August 28, 2014Date of Patent: April 7, 2020Assignee: PCI BIOTECH ASInventors: Anders Hogset, Pal Johansen
-
Patent number: 10166401Abstract: A device for activating light-induced rupture of endocytic vesicles in target cells of a patient so as to effect delivery of an administered antigen to cytosol in the target cells, is described. The device is adapted to be worn by a patient over a region of skin where an antigen and a photosensitising agent are to be administered. The device comprises a rear surface that is rounded or otherwise configured to be worn against the patient's skin. It has a retaining part for retaining the device in place over the region of the patient's skin during an activation cycle. A light source is arranged to illuminate the patient's skin from the rear of the device. A control system is configured to vary the output of the light source with respect to time in accordance with a pre-configured output sequence.Type: GrantFiled: August 28, 2014Date of Patent: January 1, 2019Assignee: PCI BIOTECH ASInventors: Anders Hogset, Per Edvard Walday, Kristin Eivindvik
-
Patent number: 9901636Abstract: The present invention relates to novel chitosan-based conjugates, e.g. nanocarriers, comprising a derivative of the biocompatible polymer chitosan conjugated to a photosensitizing agent, and uses thereof in photochemical internalization (PCI) and photodynamic therapy (PDT). The invention also relates to the use of the novel conjugates of the invention in treatment or prevention of diseases, particularly cancer, and for vaccination purposes.Type: GrantFiled: May 14, 2013Date of Patent: February 27, 2018Assignee: PCI BIOTECH ASInventors: Kristian Berg, Anders Hogset, Mar Masson, Vivek S. Gaware
-
Patent number: 9737594Abstract: The present invention provides a method of stimulating an immune response to an antigenic molecule, by contacting a cell with the antigenic molecule and with a photosensitizing agent, irradiating the cell, and thereby presenting the antigenic molecule, or part thereof, on the surface of said cell and stimulating an immune response.Type: GrantFiled: July 5, 2012Date of Patent: August 22, 2017Assignee: PCI Biotech ASInventors: Kristian Berg, Torunn E. Tjelle, Anders Hogset, Lina Prasmickaite
-
Publication number: 20160206725Abstract: A method of vaccination or immunisation involving the use of a photosensitizing agent, an antigenic molecule, e.g. a vaccine component, and an agent which enhances the effect of photochemical internalization (PCI)-mediated vaccination is disclosed wherein the agent is a ligand for a Toll-like receptor (TLR), and irradiation is with light of a wavelength effective to activate the photosensitizing agent. Antigenic, e.g. vaccine compositions, useful in such a method are also disclosed along with a method of generating antigen presenting cells which may be used to generate an immune response based on introducing antigenic molecules, e.g. vaccine components, into cells to achieve antigen presentation. The invention also provides methods of achieving vaccination in a subject using such cells.Type: ApplicationFiled: August 28, 2014Publication date: July 21, 2016Applicant: PCI Biotech ASInventors: Anders HOGSET, Pal JOHANSEN
-
Publication number: 20160199664Abstract: A device for activating light-induced rupture of endocytic vesicles in target cells of a patient so as to effect delivery of an administered antigen to cytosol in the target cells, is described. The device is adapted to be worn by a patient over a region of skin where an antigen and a photosensitising agent are to be administered. The device comprises a rear surface that is rounded or otherwise configured to be worn against the patient's skin. It has a retaining part for retaining the device in place over the region of the patient's skin during an activation cycle. A light source is arranged to illuminate the patient's skin from the rear of the device. A control system is configured to vary the output of the light source with respect to time in accordance with a pre-configured output sequence.Type: ApplicationFiled: August 28, 2014Publication date: July 14, 2016Applicant: PCI Biotech ASInventors: Anders HOGSET, Per Edvard WALDAY, Kristin EIVINDVIK
-
Publication number: 20150202293Abstract: The present invention relates to novel chitosan-based conjugates, e.g. nanocarriers, comprising a derivative of the biocompatible polymer chitosan conjugated to a photosensitising agent, and uses thereof in photochemical internalisation (PCI) and photodynamic therapy (PDT). The invention also relates to the use of the novel conjugates of the invention in treatment or prevention of diseases, particularly cancer, and for vaccination purposes.Type: ApplicationFiled: May 14, 2013Publication date: July 23, 2015Applicant: PCI BIOTECH ASInventors: Kristian Berg, Anders Hogset, Mar Masson, Vivek S. Gaware
-
Patent number: 9026203Abstract: The invention relates to pharmaceutically acceptable salts of amphiphilic photosensitizing agents which have a water solubility of at least 0.5 mg/ml and to their use in methods of photochemical internalization. Such salts may be formed from a pharmaceutically acceptable base, for example an organic amine such as an amino alcohol, or from a pharmaceutically acceptable acid, for example a sulphonic acid or a sulphonic acid derivative. Due to their increased water solubility, such salts are particularly suitable for use in the preparation of parenteral pharmaceutical preparations, e.g. for use as solutions for injection or infusion.Type: GrantFiled: August 16, 2010Date of Patent: May 5, 2015Assignee: PCI Biotech ASInventors: Jo Klaveness, Anders Hogset
-
Publication number: 20130330363Abstract: The present invention provides a method of expressing an antigenic molecule or a part thereof on the surface of an antigen-presenting cell, said method comprising introducing a molecule into the cell cytosol by photochemical internalisation, wherein said molecule, or a part thereof, is subsequently presented on the surface of said cell. Methods of vaccination comprising this method, together with compositions comprising said cells and uses involving said cells expressing antigenic molecules are also provided.Type: ApplicationFiled: July 5, 2012Publication date: December 12, 2013Applicant: PCI Biotech ASInventors: Kristian Berg, Torunn E. Tjelle, Anders Hogset, Lina Prasmickaite
-
Publication number: 20120253264Abstract: The invention relates to methods of introducing drugs into cells which are located in body cavities. In particular, it provides a photosensitizing agent for use in a method of introducing a drug molecule into the cytosol of a cell located within a body cavity, said method comprising the step of contacting said cell with said photosensitizing agent and said drug molecule, and irradiating the cell with light of a wavelength effective to activate the photosensitizing agent. Such methods are particularly suitable for use in the delivery of cytotoxic drugs in the treatment of cancer, especially bladder cancer, ovarian cancer, cervical cancer, lung cancer, brain cancer, colorectal cancer and cancers of the oral and nasal cavity.Type: ApplicationFiled: August 16, 2010Publication date: October 4, 2012Inventors: Jo Klaveness, Anders Hogset
-
Publication number: 20120226217Abstract: The invention relates to pharmaceutically acceptable salts of amphiphilic photosensitizing agents which have a water solubility of at least 0.5 mg/ml and to their use in methods of photochemical internalization. Such salts may be formed from a pharmaceutically acceptable base, for example an organic amine such as an amino alcohol, or from a pharmaceutically acceptable acid, for example a sulphonic acid or a sulphonic acid derivative. Due to their increased water solubility, such salts are particularly suitable for use in the preparation of parenteral pharmaceutical preparations, e.g. for use as solutions for injection or infusion.Type: ApplicationFiled: August 16, 2010Publication date: September 6, 2012Inventors: Jo Klaveness, Anders Hogset
-
Patent number: 8008077Abstract: The present invention provides a method for introducing a molecule into the cytosol of a cell in which the cell is contacted with a photosensitising agent, the cell is irradiated with light of a wavelength effective to activate the photosensitising agent and, substantially at the same time or after the irradiation, the cell is contacted with the molecule to be introduced, particularly for use in cancer treatment, gene therapy and vaccination.Type: GrantFiled: May 9, 2007Date of Patent: August 30, 2011Assignee: PCI Biotech ASInventors: Kristian Berg, Lina Prasmickaite, Anders Hogset, Pal Kristian Selbo
-
Publication number: 20070274953Abstract: The present invention provides a method for introducing a molecule into the cytosol of a cell in which the cell is contacted with a photosensitising agent, the cell is irradiated with light of a wavelength effective to activate the photosensitising agent and, substantially at the same time or after the irradiation, the cell is contacted with the molecule to be introduced, particularly for use in cancer treatment, gene therapy and vaccination.Type: ApplicationFiled: May 9, 2007Publication date: November 29, 2007Applicant: PCI BIOTECH ASInventors: Kristian BERG, Lina PRASMICKAITE, Anders HOGSET, Pal SELBO
-
Publication number: 20050075268Abstract: The present invention provides a method for introducing a molecule into the cytosol of a cell in which the cell is contacted with a photosentistising agent, the cell is irradiated with light of a wavelength effective to activate the photosentisitising agent and, substantially at the same time or after the irradiation, the cell is contacted with the molecule to be introduced, particularly for use in cancer treatment, gene therapy and vaccination.Type: ApplicationFiled: November 29, 2001Publication date: April 7, 2005Inventors: Kristian Berg, Lina Prasmickaite, Anders Hogset, Pal Selbo
-
Publication number: 20050002865Abstract: Targetable diagnostic and/or therapeutically active agents, e.g. ultrasound contrast agents, comprising a suspension in an aqueous carrier liquid of a reporter comprising gas-containing or gas-generating material, said agent being capable of forming at least two types of binding pairs with a target.Type: ApplicationFiled: December 15, 2003Publication date: January 6, 2005Applicant: Amersham Health ASInventors: Jo Klaveness, Pal Rongved, Anders Hogset, Helge Tolleshaug, Alan Cuthbertson, Aslak Godal, Lars Hoff, Geir Gogstad, Klaus Bryn, Anne Naevestad, Dagfinn Lovhaug, Halldis Hellebust, Magne Solbakken
-
Publication number: 20040141922Abstract: Targetable diagnostic and/or therapeutically active agents, e.g. ultrasound contrast agents, having reporters comprising gas-filled microbubbles stabilised by monolayers of film-forming surfactants, the reporter being coupled or linked to at least one vector.Type: ApplicationFiled: November 26, 2003Publication date: July 22, 2004Applicant: NYCOMED IMAGING ASInventors: Jo Klaveness, Pal Rongved, Anders Hogset, Helge Tolleshaug, Anne Naevestad, Halldis Hellebust, Lars Hoff, Alan Cuthbertson, Dagfinn Lovhaug, Magne Solbakken
-
Publication number: 20040096425Abstract: The present invention provides a method for introducing a molecule into the cytosol of a cell in which the cell is contacted with a photosensitising agent, the cell is irradiated with light of a wavelength effective to activate the photosensitising agent and, substantially at the same time or after the irradiation, the cell is contacted with the molecule to be introduced, particularly for use in cancer treatment, gene therapy and vaccination.Type: ApplicationFiled: November 28, 2003Publication date: May 20, 2004Inventors: Anders Hogset, Kristian Berg, Gunhild Mari Mlandsmo, Birgit Ovsteb?oslash; Engester, Lina Prasmickaite
-
Publication number: 20030134813Abstract: The present invention relates to a method for introducing molecules in cells by disrupting endosomal and lysosomal membranes using photodynamic treatment, without killing the majority of the cells by the photodynamic treatment. More particularly, this invention includes a method for transferring DNA and/or RNA, such as genes, to cells by photochemically inducing the disruption of endosomes and lysosomes.Type: ApplicationFiled: November 1, 2002Publication date: July 17, 2003Applicant: Photocure ASInventors: Kristian Berg, Kirsten Sandvik, Johan Moan, Anders Hogset
-
Publication number: 20020155099Abstract: The present invention relates to a method for introducing molecules in cells by disrupting endosomal and lysosomal membranes using photodynamic treatment, without killing the majority of the cells by the photodynamic treatment. More particularly, this invention includes a method for transferring DNA and/or RNA, such as genes, to cells by photochemically inducing the disruption of endosomes and lysosomes.Type: ApplicationFiled: September 1, 1998Publication date: October 24, 2002Inventors: KRISTIAN BERG, KIRSTEN SANDVIK, JOHAN MOAN, ANDERS HOGSET
-
Publication number: 20020102217Abstract: Targetable diagnostic and/or therapeutically active agents, e.g. ultrasound contrast agents, comprising a suspension in an aqueous carrier liquid of a reporter comprising gas-containing or gas-generating material, said agent being capable of forming at least two types of binding pairs with a target.Type: ApplicationFiled: August 10, 2001Publication date: August 1, 2002Applicant: Nycomed Imaging ASInventors: Jo Klaveness, Pal Rongved, Anders Hogset, Helge Tolleshaug, Alan Cuthbertson, Aslak Godal, Lars Hoff, Geir Gogstad, Klaus Bryn, Anne Naevestad, Dagfinn Lovhaug, Halldis Hellebust, Magne Solbakken